Together with Noel Courage, MI's Philip Goldbach co-authored an article published in BioTechnology Focus on IP rights and considerations surrounding antibody-based assets. As the article states: Antibodies (immunoglobulins) and other antibody-derived…
Canadian innovation will give patients affordable, non-invasive, accurate test for cancer or infectious diseases; R&D team to remain in Toronto discovery district TORONTO and SAN FRANCISCO (May 3, 2016) —…
Applications for next MSc PoP granting round being accepted until February 25, 2016 TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for…
Prima IP co-sponsoring the Ryerson University and St. Michael’s Hospital event
When your business demands staying current with the newest inventions springing up across 15 academic members, keeping pace with what’s happening is half the challenge.
That’s part of the reason why MaRS Innovation andPrima IP are sponsoring winners of an Angels’ Den competition involving the Institute for Biomedical Engineering, Science and Technology (iBEST).
iBEST is a partnership between Ryerson University and St. Michael’s Hospital that brings together Ryerson’s engineering and science strengths with St. Michael’s biomedical research and clinical expertise. The contest, which took place on June 26, 2015, riffs on the popular Dragon’s Den format.
“As a guest judge for the iBEST trainee competition this year, I reviewed a lot of thought-provoking ideas and MaRS Innovation congratulates all of the 2015 award winners,” says Dr. Fazila Seker, director of physical sciences. “Many of our portfolio technologies have their origins in this type of collaboration between researchers and medical staff, which is why we’re so excited to sponsor this competition. Fostering these types of relationships is vital to Toronto’s commercialization ecosystem.”
For the 2015 award period, MaRS Innovation will provide the competition’s winners with upfront commercialization consultation services to help shorten the time it may take for their ideas to reach the market. These services will be offered in collaboration with the technology transfer offices within St. Michael’s Hospital and the Vice-President of Research and Innovation office at Ryerson University as appropriate. In partnership with Prima IP, MaRS Innovation will also cover the initial patent application preparation and filing for the top two awardees of the iBEST event. Future award winners will receive similar support.
“Canada’s future economy depends on programs that encourage and facilitate innovation allowing Canada to remain competitive in the global marketplace and attract foreign investment,” said Marcelo König Sarkis, principal, founder and senior patent agent at Prima IP. “We are passionate in our support for Canadian inventions from the initial research phase to start-up and beyond.”
Toronto-based commercial arm of BioDiaspora research program tracks global spread of infectious diseases in real-time; fourth MI company to reach Series A
TORONTO (Dec. 2, 2014) — BlueDot, a Toronto-based social benefit corporation founded by Dr. Kamran Khan, an infectious disease physician and scientist, tracks and predicts the global spread of infectious diseases.
Spun off from St. Michael’s Hospital in partnership with MaRS Innovation (and formerly known as BioDiaspora Inc.), BlueDot, has secured a Series A venture capital funding from Horizons Ventures. Funded by Sir Li Ka-shing, Horizons invests in what they call “game-changing disruptive tech,” and has a proven track record in making early-stage investments (i.e., Facebook, Skype, Waze, Siri and Spotify).
The company is the fourth in MaRS Innovation’s portfolio to reach Series A. MaRS Innovation provided $400,000 in seed funding and worked with BlueDot and St. Michael’s to incorporate the company and develop its initial business strategy, intellectual property protection strategy and go-to-market plan. The Ontario Centres of Excellence also provided $140,000 in commercialization grants that helped BlueDot get off the ground.
BlueDot is the commercial arm of Dr. Khan’s academic research program called BioDiaspora, which was developed at the Li Ka Shing Knowledge Institute of St. Michael’s. BioDiaspora models how infectious diseases can spread and impact populations globally by analyzing big data such as the annual movements of more than 3 billion travelers on commercial flights; human, animal and insect population data; climate data from satellites; and news reports of disease outbreaks. The program was inspired by the Toronto’s SARS crisis in 2003 and its capabilities scientifically validated in prestigious academic journals such as the Lancet and the New England Journal of Medicine.
Visualization of the final destinations of travelers departing countries in West Africa with widespread and intense Ebola virus transmission. Source: http://bluedot.global/work
During its development, BlueDot’s platform technology was used by numerous international agencies, including the U.S. Centers for Disease Control, the World Health Organization, the European Centre for Disease Prevention and Control and the Public Health Agency of Canada to evaluate emerging infectious disease threats, including those during global mass gatherings such as the Olympics and the hajj.
Article focuses on importance of intellectual property protection for small businesses
Dr. Stacey Ivanchuk, director of intellectual property for MaRS Innovation.
Dr. Stacey Ivanchuk, MaRS Innovation’s director of intellectual property, was quoted in Denise Deveau’s article, “Intellectual property protection is a game small businesses can’t afford to lose,” for the FinancialPost on September 26, 2014 regarding the importance of protecting intellectual property for small businesses.
Here’s an excerpt:
Stacey Ivanchuk, director of intellectual property for MaRS Innovation in Toronto, says that protecting a startup’s technology is important especially from an investor’s perspective.
“One of the first questions investors will ask a company is, what is your IP position? To them it’s something they can talk about as an asset and shows that you are distinguishing yourself,” [Dr.] Ivanchuk said.
Ivanchuk said businesses run the gamut from doing nothing to protect their ideas to filing for patents on every idea that comes out of a brainstorming session. “Too early is not good because it can be a waste of money if the proof you expected down the road doesn’t happen,” she said. “But if you wait too long someone might beat you to the punch.”
The article also quotes Atul Asthana, CEO of Kaypok, a tech start-up in the text analytics space spun out from York University in partnership with MaRS Innovation:
In the high tech world especially, it’s not always easy to determine whether something should be protected or not, according to Mr. Asthana. “You have to be able to enforce it. If you do it poorly, you will be giving your ideas away and spending a whole bunch of money. It can become a real cat and mouse game sometimes,” he said.
Dr. Raphael Hofstein, president & CEO, MaRS Innovation.
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Dr. Raphael Hofstein.
The article explores the role life sciences assets, financing and talented management–the three Ms–must play in revitalizing Canada’s biotechnology sector:
At the close of the 20th century, Canada was perceived as a key contributor to the success of the global biotech voyage.
You know what happened next: the mechanisms to fund early ventures collapsed together with the collapse of the Canadian venture capital industry Finding suitable investment for early-stage technologies became incredibly challenging. Facing a dearth of opportunity, talented management sailed for other harbors.
It’s satisfying that on the eve of the 2014 BIO Convention, some indicators suggest to me that we are witnessing a rebound. But to accelerate our pace while holding this bearing, Canada needs to address certain strategic elements.
At MaRS Innovation, we call them the three Ms: merchandize, management and money.
Red Herring Top 100 America recognizes innovation from outstanding entrepreneurs and promising companies. Its “Top 100 North America” award winners were selected from among approximately 3,000 tech start-ups financed each year in the U.S. and Canada. Past winners include companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, Marin Software, Palo Alto Networks and eBay, and many others that have changed how we live and work.
“In 2014, selecting the top 100 achievers was by no means a small feat,” said Alex Vieux, publisher and CEO of Red Herring. “We believe Flybitsembodies the vision, drive and innovation that define a successful entrepreneurial venture. Flybitsshould be proud of its accomplishment, as the competition was very strong.”
MaRS Innovation and U of T's Innovations & Partnerships Office collaborating with QSperm on intellectual property and business strategy In vitro fertility treatments can be intensely emotional and medically invasive,…
Deal led by MaRS Innovation and Innovation York to strengthen Slyce’s mobile image recognition application for retail e-commerce
York’s technology will help Slyce in developing a mobile app that can be used to take pictures of a product in-store, enabling a user to purchase the item from the retailer immediately on his or her smartphone.
TORONTO, Feb. 4, 2014—Slyce today announced that it has acquired a computer vision technology developed at York University that quickly analyzes and aggregates similar images.
Through the acquisition, Slyce also hired former York PhD student, Dr. Ehsan Fazl-Ersi, to lead the integration of the intellectual property into Slyce’s Visual Search Platform as their new head of Research & Development.
Slyce is a premium provider of visual search technology for retailers, brands and publishers. Their platform allows customers to take a picture of real-world products with their smartphone and then find direct or close-matching products from the retailer’s catalogue, which they are able to purchase on the spot.
“Identifying and classifying an object captured within a scene is difficult due to the effects of background clutter, lighting variations and viewpoint changes on the object’s appearance,” says Fazl-Ersi, who designed and developed the technology with his PhD supervisor, Dr. John K. Tsotsos, a professor in the Lassonde School of Engineering’s Department of Electrical Engineering and Computer Science, and a member and former director of York’s Centre for Vision Research.
“This is a much bigger problem for mobile applications where the algorithm’s speed and efficiency are the difference between losing a consumer or making a sale,” says Fazl-Ersi. “Our technology will provide higher accuracy when quickly identifying retail items so that consumers can choose among similar items according to style, colour or pattern using a mobile device.”
The researchers partnered with MaRS Innovation and Innovation York, York’s commercialization office, to file patent protection on the initial technology, develop a commercialization plan, secure grant funding, facilitate business development meetings and negotiate the resulting transaction.